ISSN: 1859 - 2872
Results of the treatment of psoriasis vulgaris with infliximab at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: To evaluate the therapeutic efficacy and undesirable effects of infliximab in patients with moderate-severe psoriasis vulgaris. Subject and method: A cross-sectional study; 18 patients with moderate-severe psoriasis vulgaris; For patients with psoriasis, infliximab is infused at a dose of 5mg/kg at week 0, 2 and 6 and then at 8 weekly intervals thereafter. Evaluate the therapeutic effect and undesirable effects before each infusion. Result: At week 14, 64.3% of patients achieved PASI 75, of which 21.4% achieved PASI 100, 35.7% of patients achieved DLQI 0. Serious adverse drug reaction that may be experienced are anaphylactic shock, muscle pain, Guillain-Barré syndrome and acute urticaria. The most common reason to stop treatment was financial reasons. Conclusion: Infliximab is an effective treatment for psoriasis vulgaris.
Article Details
References
2. Feldman SR, Gordon KB, Bala M et al (2005) Infliximab results in significant improvement in the quality of life of patients with severe psoriasis: a double - blind placebo-controlled trial. J Am Acad Dermatol 152: 954-960.
3. Gottlieb AB, Evans R, Li S et al (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomised double-blind, placebo-controlled trial. J Am Acad Dermatol 51: 534-542.
4. Menter A, Feldman SR, Weinstein GD et al (2007) A randomised comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-severe plaque psoriasis. J Am Acad Dermatol 56(31): 1-15.
5. Mahil SK, Capon F, Barker JN (2016) Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 38(1): 11-27. doi:10.1007/s00281-015-0539-8.
6. Mohan N, Edwards ET, Cupps TR et al (2001) Demyelination occurring during anti-tumour necrosis factor alpha for inflammatory arthritidies. Arthritis Rheum 44: 2862-2869.
7. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 133(2): 377-385. doi:10.1038/ jid.2012.339.
8. Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 366: 1367-1374.
Article Sidebar
